DK0722722T4 - Anvendelse af en antagonist for P-substans til behandling af kutan rødme af neurogen oprindelse - Google Patents

Anvendelse af en antagonist for P-substans til behandling af kutan rødme af neurogen oprindelse

Info

Publication number
DK0722722T4
DK0722722T4 DK95402582T DK95402582T DK0722722T4 DK 0722722 T4 DK0722722 T4 DK 0722722T4 DK 95402582 T DK95402582 T DK 95402582T DK 95402582 T DK95402582 T DK 95402582T DK 0722722 T4 DK0722722 T4 DK 0722722T4
Authority
DK
Denmark
Prior art keywords
treat cutaneous
cutaneous redness
substance antagonist
neurogenic origin
neurogenic
Prior art date
Application number
DK95402582T
Other languages
Danish (da)
English (en)
Other versions
DK0722722T3 (da
Inventor
Lacharriere Olivier De
Lionel Breton
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9469930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0722722(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oreal filed Critical Oreal
Publication of DK0722722T3 publication Critical patent/DK0722722T3/da
Application granted granted Critical
Publication of DK0722722T4 publication Critical patent/DK0722722T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK95402582T 1994-12-19 1995-11-17 Anvendelse af en antagonist for P-substans til behandling af kutan rødme af neurogen oprindelse DK0722722T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9415252A FR2728165A1 (fr) 1994-12-19 1994-12-19 Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene

Publications (2)

Publication Number Publication Date
DK0722722T3 DK0722722T3 (da) 1999-06-14
DK0722722T4 true DK0722722T4 (da) 2003-07-07

Family

ID=9469930

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95402582T DK0722722T4 (da) 1994-12-19 1995-11-17 Anvendelse af en antagonist for P-substans til behandling af kutan rødme af neurogen oprindelse

Country Status (15)

Country Link
US (1) US5744156A (enExample)
EP (1) EP0722722B2 (enExample)
JP (1) JPH08208508A (enExample)
AR (1) AR000357A1 (enExample)
AT (1) ATE171372T1 (enExample)
BR (1) BR9505381A (enExample)
CA (1) CA2165518C (enExample)
DE (1) DE69504949T3 (enExample)
DK (1) DK0722722T4 (enExample)
ES (1) ES2124983T5 (enExample)
FR (1) FR2728165A1 (enExample)
HU (1) HU218944B (enExample)
MX (1) MX9505192A (enExample)
PL (1) PL311917A1 (enExample)
RU (1) RU2140263C1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732221B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2738742B1 (fr) * 1995-09-19 1997-11-14 Oreal Utilisation d'au moins une eau thermale de vichy en tant qu'antagoniste de substance p
US7419683B2 (en) * 1997-10-31 2008-09-02 United States Of America As Represented By The Secretary Of The Army Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
FR2774285B1 (fr) 1998-02-03 2001-06-15 Roche Posay Lab Pharma Utilisation d'une composition cosmetique pour le traitement et la prevention de la rosacee
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
TW537894B (en) * 1998-05-26 2003-06-21 Novartis Ag A spontaneously dispersible pharmaceutical composition comprising a piperidine substance P antagonist
DE10025553A1 (de) * 2000-05-24 2001-11-29 Merck Patent Gmbh Zusammensetzung, enthaltend mindestens ein Aryloxim und mindestens einen Wirkstoff zur Behandlung von Akne und ihre Verwendung
US20040259850A1 (en) * 2001-10-31 2004-12-23 Alves Stephen E. Method for treating or preventing symptoms of hormonal variation including hot flashes
FI116772B (fi) * 2003-03-17 2006-02-28 Psorioil Ltd Oy Hilseilevälle iholle tarkoitettu mäntyrasvahappoja sisältävä voidemainen tai öljymäinen hoitovalmiste
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
EP1600158A1 (en) * 2004-05-26 2005-11-30 Galderma Research & Development, S.N.C. Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof
FR2866566A1 (fr) * 2004-02-20 2005-08-26 Galderma Res & Dev Utilisation d'un inhibiteur de la secretion d'il-5,il-6 et/ou il-10 pour le traitement de la rosacee
WO2007062060A2 (en) 2005-11-22 2007-05-31 Ted Reid Methods and compositions using substance p to promote wound healing
WO2007137117A2 (en) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
WO2008047709A1 (fr) 2006-10-16 2008-04-24 Lion Corporation Composition antagoniste du récepteur de la nk1

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5921656A (ja) 1982-07-28 1984-02-03 Takeda Chem Ind Ltd ポリペプチド誘導体
US4472305A (en) 1983-05-17 1984-09-18 Sterling Drug Inc. Hexapeptide amides
US4839465A (en) 1987-01-20 1989-06-13 Sterling Drug Inc. Di-(D-tryptophyl and/or tetrahydropyridoindolylcarbonyl)-containing peptide amides and process for preparation thereof
GB8807921D0 (en) 1988-04-05 1988-05-05 Fujisawa Pharmaceutical Co Ws-9326 & its derivatives
US5187156A (en) 1988-03-16 1993-02-16 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
GB8807246D0 (en) 1988-03-25 1988-04-27 Merck Sharp & Dohme Therapeutic agents
EP0360390A1 (en) † 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
MX18467A (es) 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5164372A (en) 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
FR2654725B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2654726B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone et leur preparation.
GB8929070D0 (en) 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
WO1991009844A1 (en) 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
US5321032A (en) 1990-02-15 1994-06-14 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds and pharmaceutical compositions thereof
JPH0794439B2 (ja) 1990-05-31 1995-10-11 フアイザー・インコーポレイテツド 置換ピペリジンの製造法
HUT62891A (en) 1990-06-01 1993-06-28 Pfizer Process for producing 3-amino-2-arylquinuclidine compounds and pharmaceuticql composition comprising such compounds
EP0498069B1 (en) 1990-12-21 1995-10-25 Fujisawa Pharmaceutical Co., Ltd. New use of peptide derivative
AU652407B2 (en) 1991-01-10 1994-08-25 Pfizer Inc. N-alkyl quinuclidinium salts as substance P antagonists
EP0499313B1 (en) 1991-02-11 1997-06-11 MERCK SHARP & DOHME LTD. Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
EP0573522B1 (en) 1991-03-01 1994-12-14 Pfizer Inc. 1-azabicyclo[3.2.2]nonan-3-amine derivatives
SK284565B6 (sk) 1991-03-26 2005-06-02 Pfizer Inc. Spôsob prípravy substituovaných piperidínov
FR2677361A1 (fr) 1991-06-04 1992-12-11 Adir Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2676447B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives du thiopyranopyrrole et leur preparation.
FR2676446B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives du thiopyranopyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2676443B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole et leur preparation.
FR2676442B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
CZ247993A3 (en) 1991-05-22 1994-07-13 Pfizer Substituted 3-aminoquinuclidine derivatives, process of their preparation and use thereof
GB9113219D0 (en) 1991-06-19 1991-08-07 Fujisawa Pharmaceutical Co Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
CA2109613C (en) 1991-06-20 1996-11-19 John Adams Lowe Iii Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
TW202432B (enExample) 1991-06-21 1993-03-21 Pfizer
US5288730A (en) † 1991-06-24 1994-02-22 Merck Sharp & Dohme Limited Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
EP0522808A3 (en) † 1991-07-05 1993-01-27 MERCK SHARP & DOHME LTD. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
JPH06509087A (ja) 1991-07-05 1994-10-13 メルク　シヤープ　エンド　ドーム　リミテツド 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用
US5495047A (en) † 1991-07-10 1996-02-27 Merck, Sharp & Dohme (Ltd.) Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
EP0600952B1 (en) 1991-08-20 1996-04-17 MERCK SHARP & DOHME LTD. Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
DE69232588T2 (de) 1991-09-26 2002-08-22 Pfizer Inc., New York Kondensierte trizyklische, stickstoffenthaltende Verbindungen als Substanz P Rezeptor Antagonisten
WO1993009116A1 (fr) 1991-11-07 1993-05-13 Yoshitomi Pharmaceutical Industries, Ltd. Compose a base de quinuclidine et utilisation dudit compose en medecine
CA2123403C (en) * 1991-11-12 2002-02-05 Brian T. O'neill Acyclic ethylenediamine derivatives as substance p receptor antagonists
CA2083891A1 (en) 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
GB9201179D0 (en) † 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
JPH05339240A (ja) * 1992-06-04 1993-12-21 Yamanouchi Pharmaceut Co Ltd テトラヒドロイソキノリンアミド誘導体
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
GB9222486D0 (en) † 1992-10-26 1992-12-09 Merck Sharp & Dohme Therapeutic agents
DE69405862T2 (de) * 1993-05-06 1998-01-15 Merrell Pharma Inc Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten
FR2719474B1 (fr) † 1994-05-05 1996-05-31 Oreal Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.

Also Published As

Publication number Publication date
HU218944B (hu) 2001-01-29
EP0722722A1 (fr) 1996-07-24
PL311917A1 (en) 1996-06-24
DK0722722T3 (da) 1999-06-14
DE69504949D1 (de) 1998-10-29
FR2728165A1 (fr) 1996-06-21
JPH08208508A (ja) 1996-08-13
AR000357A1 (es) 1997-06-18
ES2124983T3 (es) 1999-02-16
RU2140263C1 (ru) 1999-10-27
FR2728165B1 (enExample) 1997-02-07
DE69504949T2 (de) 1999-02-18
CA2165518C (fr) 2002-07-16
US5744156A (en) 1998-04-28
CA2165518A1 (fr) 1996-06-20
HU9503625D0 (en) 1996-02-28
DE69504949T3 (de) 2004-01-15
EP0722722B1 (fr) 1998-09-23
ES2124983T5 (es) 2003-11-16
EP0722722B2 (fr) 2003-03-05
MX9505192A (es) 1997-04-30
ATE171372T1 (de) 1998-10-15
BR9505381A (pt) 1997-11-18
HUT74948A (en) 1997-03-28

Similar Documents

Publication Publication Date Title
DK0734729T4 (da) Anvendelse af en CGRP-antagonist til behandling af hudrödme af neurogen oprindelse og den opnåede sammensætning
DK0722722T3 (da) Anvendelse af en antagonist for P-substans til behandling af kutan rødme af neurogen oprindelse
FI963228A7 (fi) Substituoituja bifenyylijohdannaisia fosfodiesteraasi-inhibiittoreina
DE69718480D1 (de) Heterocyclische metalloprotease inhibitoren
PT1049695E (pt) Imidazotriazinonas 2-fenil substituidas enquanto inibidores de fosfodiesterase
FI962800L (fi) Fenyyliheterosyklisiä yhdisteitä COX-2 inhibiittoreina
DK0923561T3 (da) Heterocykliske metalloproteaseinhibitorer
DK0970095T3 (da) Hidtil ukendte benzimidazolinhibitorer for fructose-1,6-bisphosphase
LV12102A (lv) Rotamazes funkciju inhibitori
DE69525254D1 (de) Substituierte oxim-derivate verwendbar als pde iv hemmer
DK0722736T3 (da) Topisk sammensætning indeholdende en antagonist for substans P
DE69627179T2 (de) Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren
DE69725465D1 (de) 6-phenylpyridyl-2-amin-derivate verwendbar als nos-inhibitoren
DK1114051T3 (da) Inhibitorer for p38
ATE216997T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
DE69716916D1 (de) Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
ATE202347T1 (de) Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren
ATE267805T1 (de) Lactamverbindungen als metalloprotease- inhibitoren
FI972151A0 (fi) Kannettava laite kehollisen juoksevan väliaineen ex tempore-analyysiä varten
PT927183E (pt) Inibidores espirociclicos de metaloproteases
DE69315662D1 (de) Aminderivate als Korrosionsinhibitoren
ATE205836T1 (de) Bicyclische 4-aralkylaminopyrimidin-derivate als tyrosinkinase-inhibitoren
DE69728139T2 (de) Pyrrolopyrrolone als inhibitoren von neutrophiler elastase
IS2230B (is) Aukinn stöðugleiki lausna til inndælingar
DE60034708D1 (de) Gerät zur lebensdauerschätzung von hilfsbatterien